Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Vir Biotechnology Inc (VIR)

Vir Biotechnology Inc (VIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
From laggards to leaders: Small caps on the rise

Despite large-cap dominance, signs suggest a shift to small-cap leadership. Valuations, positive Q3 results, and historical patterns point to potential gains.

MDY : 547.97 (+1.05%)
TSLA : 171.97 (-1.57%)
XLC : 81.67 (+0.50%)
IWM : 205.86 (+1.02%)
RCL : 141.74 (+0.04%)
XLK : 204.78 (-0.03%)
NVDA : 887.47 (-1.84%)
META : 475.42 (+0.60%)
SPSM : 42.66 (+1.21%)
SPY : 520.17 (+0.58%)
VIR : 9.56 (+0.21%)
RCUS : 16.15 (+5.83%)
The Five Biotech Stocks Every Investor Should Know About

Avalon GloboCare Corp., (NASDAQ: ALBT) a developer of innovative precision diagnostics and provider of clinical laboratory services just announced that the United States Patent and Trademark Office (USPTO)...

ALBT : 0.2777 (-0.89%)
INSM : 26.38 (+1.46%)
VIR : 9.56 (+0.21%)
CODX : 1.2300 (+0.82%)
ANTX : 2.47 (+1.23%)
A Potentially Revolutionary Tuberculosis Test Can Produce Results in 24 Hours

With a rising prevalence of chronic diseases, we’re starting to see higher demand for clinical lab services. That being said, it’s no surprise that, according to Market.Us, the global market for clinical...

INSM : 26.38 (+1.46%)
VIR : 9.56 (+0.21%)
CODX : 1.2300 (+0.82%)
ANTX : 2.47 (+1.23%)
ALBT : 0.2777 (-0.89%)
Is Vir Biotechnology Stock a Buy?

The biotech is out to prove that it isn't just a "pandemic stock."

VIR : 9.56 (+0.21%)
Why Shares of Vir Biotechnology Are Plunging Thursday

The company had disappointing trial news for one of its lead therapies.

GSK : 44.67 (+1.20%)
GILD : 64.58 (-0.52%)
VIR : 9.56 (+0.21%)
Brii Biosciences Provides Latest Clinical Development and Corporate Updates

Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from...

VIR : 9.56 (+0.21%)
VBIV : 0.6033 (+0.55%)
ANTX : 2.47 (+1.23%)
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASLâ„¢ Congress 2023

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio", "we", or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...

VIR : 9.56 (+0.21%)
VBIV : 0.6033 (+0.55%)
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -30.86% and 64.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

VIR : 9.56 (+0.21%)
RETA : 172.36 (+0.02%)
Twist Bioscience (TWST) Expected to Beat Earnings Estimates: Should You Buy?

Twist Bioscience (TWST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TWST : 43.20 (+4.35%)
VIR : 9.56 (+0.21%)
Earnings Preview: Vir Biotechnology, Inc. (VIR) Q1 Earnings Expected to Decline

Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VIR : 9.56 (+0.21%)

Barchart Exclusives

1 Dividend Aristocrat to Buy for Double-Digit Earnings Growth
Discover why Ecolab's recent earnings beat, along with its robust dividend history, make it a standout choice for investors seeking a blend of growth and stability in 2024. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar